Download full-text PDF

Source
http://dx.doi.org/10.1007/s12020-019-01874-4DOI Listing

Publication Analysis

Top Keywords

acromegaly cured
4
cured first-line
4
first-line pasireotide
4
pasireotide treatment?
4
acromegaly
1
first-line
1
pasireotide
1
treatment?
1

Similar Publications

Sclerostin and OPG/RANK-L system take part in bone remodeling in patients with acromegaly.

Front Endocrinol (Lausanne)

January 2025

Department and Clinic of Endocrinology, Diabetes and Isotope Therapy, Wroclaw Medical University, Wrocław, Poland.

Article Synopsis
  • Acromegaly is marked by increased bone turnover and higher vertebral fracture risk, with sclerostin inhibiting bone formation and playing a role in the OPG/RANK-L system that regulates bone metabolism.
  • The study investigated levels of sclerostin, osteoprotegerin (OPG), and RANK-L in 126 patients with varying acromegaly activity, aiming to explore connections between sclerostin and bone health.
  • Results showed lower sclerostin levels in acromegaly patients compared to controls, with notable differences in OPG levels across groups but no significant changes in RANK-L; a positive correlation was found between sclerostin and OPG in patients with various acromegaly
View Article and Find Full Text PDF

: In pituitary adenomas, examinations of surgical specimens have shown that dural invasion occurs in 42-85% of cases. No studies about dura mater invasion have been conducted specifically in acromegaly patients. The aim of the present study was to evaluate the relationship between histologically dural invasion and the main features of GH-secreting adenomas.

View Article and Find Full Text PDF

Prevalence of Neoplasms in Patients with Acromegaly-A Single-Center Polish Study.

J Clin Med

November 2024

Department and Clinic of Endocrinology and Internal Medicine, Wroclaw Medical University, Wybrzeże Pasteura 4, 50-367 Wroclaw, Poland.

Article Synopsis
  • Neoplasms are a leading cause of death in patients with acromegaly, which prompted this study to analyze the incidence and types of benign and malignant tumors in these patients.
  • Researchers examined the relationship between tumor prevalence, disease activity, diagnosis timing, and symptom onset, alongside hormone levels from the pituitary gland.
  • The study involved a review of records from 230 acromegaly patients in Poland, revealing significantly higher rates of both benign and malignant neoplasms in active cases compared to those who had been cured.
View Article and Find Full Text PDF

Novel approach to bone comorbidity in resistant acromegaly.

Pituitary

December 2024

Institute of Endocrine and Metabolic Sciences, Università Vita-Salute San Raffaele, Via Olgettina, 58, Milan, 20132, Italy.

Article Synopsis
  • Active acromegaly can cause serious, irreversible complications like osteopathy and fragile fractures, which are linked to longer disease duration and high growth hormone levels.
  • Unlike primary osteoporosis, bone mineral density isn't a good predictor for fracture risk in acromegaly patients, as they often have normal or only slightly reduced bone mass, but compromised bone quality.
  • The manuscript aims to review evidence on skeletal fragility in patients with active and resistant acromegaly, highlighting the need for disease control and potential protective effects from vitamin D and pasireotide therapies.
View Article and Find Full Text PDF

Introduction: The purpose of this study was to evaluate the impact of disease activity and gonadal status on bone mineral density (BMD) and turnover markers (BTMs) in individuals with acromegaly.

Materials And Methods: Subjects underwent laboratory tests for PTH, 25-hydroxyvitamin D, calcium, phosphorus, osteocalcin (OC) and C-telopeptide (CTX-1) and bone densitometry at the lumbar spine (LS), femoral neck (FN) and total hip (TH).

Results: Sixty participants (48.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!